(Q28238474)

English

CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients

scientific article (publication date: August 2009)

In more languages

Statements

scholarly article

0 references

CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients (English)

0 references

0 references

polycythemia vera

1 reference

based on heuristic

inferred from title

6

object named as

A Tefferi

0 references

author name string

A Pardanani

1

0 references

T Lasho

2

0 references

G Smith

3

0 references

C J Burns

4

0 references

E Fantino

5

0 references

language of work or name

0 references

publication date

August 2009

0 references

0 references

23

0 references

8

0 references

1441-5

0 references

JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis

1 reference

https://api.crossref.org/works/10.1038/LEU.2009.50

21 April 2017

A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome

1 reference

https://api.crossref.org/works/10.1038/LEU.2009.50

21 April 2017

Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera.

1 reference

https://api.crossref.org/works/10.1038/LEU.2009.50

21 April 2017

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.50

21 April 2017

Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.50

21 January 2018

Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.50

21 January 2018

Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.50

21 January 2018

Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.50

21 January 2018

Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.50

21 January 2018

JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.50

21 January 2018

TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.50

21 January 2018

TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.50

21 January 2018

Concurrent MPL515 and JAK2V617F mutations in myelofibrosis: chronology of clonal emergence and changes in mutant allele burden over time.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.50

21 January 2018

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q28238474&oldid=2175147384"